P.D.: Por si interesa a alguien hoy Ahorro y corporacion y recojido en la web de capital Bolsa informa de que las aprobaciones conseguidas ayer por Yondelis son una noticia positiva para Zeltia y su Recomendacion es la de " Comprar " con un Precio Objetivo de 3,90 euros .
************************************************************
Sample drugs considered : Champix, Abilify, Cymbalta, Gardasil , Yondelis , Actemra/Ro-Actemra, Brilinta/Brilique, Ilaris, Prolia, Victoza, Votrient, Daxas, Kuvan, Jevtana, Byetta, Uloric/Adenuric, Gilenya, Cimzia, Banzel/Inovelon, Rapaflo/Silodyx/Urorex, Orencia, and Sprycel.
A consideration of why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals .
This briefing contributes to the current debate around IP rights for pharmaceuticals in Canada.
Against the backdrop of the CETA trade negotiations, Norton Rose Group's Toronto-based head of pharmaceuticals and life sciences, Patrick E. Kierans, and colleagues Kristin Wall and Jill Daley employ a comparative study to highlight why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals.
On average, the EU is approving new drugs faster and enabling patent term restoration, leaving Canadian innovators doubly disadvantaged compared with their second-largest trading partner. Implementing patent term restoration and extending the term of data protection will help to level the playing field with Europe. For the majority of the sampled products, extending data protection by two years appears to provide greater security for innovators without extending overall IP exclusivity for innovative medicines. Increasing the rate of drug approval in Canada will diminish any market exclusivity impact of data protection and patent term restoration, while giving Canadians earlier access to new medicines.
...
RESULTADOS DE UN ESTUDIO SOBRE IMFORTE Y SI ES VIABLE EL COSTE-EFECTIVIDAD DE ATEZOLIZUMAB/LURBINECTEDIN PARA EL TRATAMIENTO DE MANTENIMIENTO EN PRIMERA LINEA PARA LOS SISTEMAS DE SALUD DE ESTADOS UNIDOS Y CHINA . CONCLUSIÓN : SU ALTO COSTO LA HACE INSOSTENIBLE Y NO RENTABLE . ///.../// ///.../// TOCA FELICITAR ... ¿ PERO A QUIEN ? ... ¿ A LOS QUE ALEGREMENTE LAS ESTAN VENDIENDO ... O A LOS QUE TAMBIÉN ALEGREMENTE SE LAS ESTÁN.COMPRANDO ... ? . ¡ FELICIDADES !!..